Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas.

Santos-Pinheiro F, Park M, Liu D, Kwong LN, Cruz S, Levine NB, O'Brien BJ, Chen M.

Neurooncol Pract. 2019 May;6(3):209-217. doi: 10.1093/nop/npy022. Epub 2018 Jul 9.

PMID:
31386048
2.

A fatty acid oxidation-dependent metabolic shift regulates the adaptation of BRAF-mutated melanoma to MAPK inhibitors.

Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ.

Clin Cancer Res. 2019 Aug 2. pii: clincanres.0253.2019. doi: 10.1158/1078-0432.CCR-19-0253. [Epub ahead of print]

PMID:
31375515
3.

Correction: In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 Dec;8(12):1654. doi: 10.1158/2159-8290.CD-18-1291. No abstract available.

PMID:
30510016
4.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

5.

BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.

Romano G, Kwong LN.

Cancer Discov. 2018 Sep;8(9):1064-1065. doi: 10.1158/2159-8290.CD-18-0784.

6.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N.

Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.

7.

Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma.

Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW.

Clin Cancer Res. 2018 Oct 1;24(19):4771-4784. doi: 10.1158/1078-0432.CCR-17-2773. Epub 2018 Mar 21.

PMID:
29563139
8.

A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.

Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN.

Cancer Discov. 2018 May;8(5):556-567. doi: 10.1158/2159-8290.CD-17-0745. Epub 2018 Mar 1.

9.

In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.

Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE.

Cancer Discov. 2018 May;8(5):568-581. doi: 10.1158/2159-8290.CD-17-0699. Epub 2018 Mar 1. Erratum in: Cancer Discov. 2018 Dec;8(12):1654.

10.

The path to metastatic mouse models of colorectal cancer.

Romano G, Chagani S, Kwong LN.

Oncogene. 2018 May;37(19):2481-2489. doi: 10.1038/s41388-018-0155-x. Epub 2018 Feb 21. Review.

PMID:
29463860
11.

Crosstalk between the Notch signaling pathway and long non-coding RNAs.

Reicher A, Foßelteder J, Kwong LN, Pichler M.

Cancer Lett. 2018 Apr 28;420:91-96. doi: 10.1016/j.canlet.2018.01.070. Epub 2018 Feb 2. Review.

PMID:
29409809
12.

Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas.

Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00259. Epub 2018 Jun 14.

13.

Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy.

Romano G, Kwong LN.

Cancer Metastasis Rev. 2018 Mar;37(1):45-53. doi: 10.1007/s10555-017-9716-7. Review.

PMID:
29270700
14.

miRNAs, Melanoma and Microenvironment: An Intricate Network.

Romano G, Kwong LN.

Int J Mol Sci. 2017 Nov 7;18(11). pii: E2354. doi: 10.3390/ijms18112354. Review.

15.

Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS.

Yun C, Dashwood WM, Kwong LN, Gao S, Yin T, Ling Q, Singh R, Dashwood RH, Hu M.

J Pharm Biomed Anal. 2018 Jan 30;148:42-50. doi: 10.1016/j.jpba.2017.07.025. Epub 2017 Jul 25.

16.

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN.

Cell Rep. 2017 Jun 27;19(13):2878-2880. doi: 10.1016/j.celrep.2017.06.008. No abstract available.

17.

Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma.

Kwong LN, Zou L, Chagani S, Pedamallu CS, Liu M, Jiang S, Protopopov A, Zhang J, Getz G, Chin L.

Cell Rep. 2017 May 16;19(7):1304-1312. doi: 10.1016/j.celrep.2017.04.065.

18.

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN.

Cell Rep. 2017 Mar 14;18(11):2780-2794. doi: 10.1016/j.celrep.2017.02.033. Erratum in: Cell Rep. 2017 Jun 27;19(13):2878-2880.

19.

Oncogenic Kras drives invasion and maintains metastases in colorectal cancer.

Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RA.

Genes Dev. 2017 Feb 15;31(4):370-382. doi: 10.1101/gad.293449.116. Epub 2017 Mar 13.

20.

Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients.

Richtig G, Hoeller C, Kashofer K, Aigelsreiter A, Heinemann A, Kwong LN, Pichler M, Richtig E.

Br J Dermatol. 2017 Oct;177(4):936-944. doi: 10.1111/bjd.15436. Epub 2017 Sep 4. Review.

PMID:
28278349
21.

Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.

Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L.

Nature. 2017 Feb 16;542(7641):362-366. doi: 10.1038/nature21064. Epub 2017 Feb 8.

PMID:
28178232
22.

Loss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability.

Chen J, Shukla V, Farci P, Andricovich J, Jogunoori W, Kwong LN, Katz LH, Shetty K, Rashid A, Su X, White J, Li L, Wang AY, Blechacz B, Raju GS, Davila M, Nguyen BN, Stroehlein JR, Chen J, Kim SS, Levin H, Machida K, Tsukamoto H, Michaely P, Tzatsos A, Mishra B, Amdur R, Mishra L.

Hepatology. 2017 Feb;65(2):678-693. doi: 10.1002/hep.28927. Epub 2016 Dec 24.

23.

Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.

Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ.

J Gastrointest Oncol. 2016 Dec;7(6):819-827. doi: 10.21037/jgo.2016.11.11. No abstract available.

24.

Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.

Jain A, Kwong LN, Javle M.

Curr Treat Options Oncol. 2016 Nov;17(11):58. Review.

PMID:
27658789
25.

Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.

Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S.

Oncotarget. 2016 Jun 28;7(26):39595-39608. doi: 10.18632/oncotarget.9153.

26.

Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA.

Cancer Discov. 2016 Aug;6(8):827-37. doi: 10.1158/2159-8290.CD-15-1545. Epub 2016 Jun 14.

27.

Oncogenic BRAF-Mediated Melanoma Cell Invasion.

Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W.

Cell Rep. 2016 May 31;15(9):2012-24. doi: 10.1016/j.celrep.2016.04.073. Epub 2016 May 19.

28.

Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression.

Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN.

Sci Rep. 2016 Jan 20;6:19649. doi: 10.1038/srep19649.

29.

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL Jr, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P.

Cancer Discov. 2016 Feb;6(2):202-16. doi: 10.1158/2159-8290.CD-15-0283. Epub 2015 Dec 8.

30.

Dual Roles of RNF2 in Melanoma Progression.

Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L.

Cancer Discov. 2015 Dec;5(12):1314-27. doi: 10.1158/2159-8290.CD-15-0493. Epub 2015 Oct 8.

31.

Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.

Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L.

J Clin Invest. 2015 Apr;125(4):1459-70. doi: 10.1172/JCI78954. Epub 2015 Feb 23.

32.

Systematic identification of signaling pathways with potential to confer anticancer drug resistance.

Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC.

Sci Signal. 2014 Dec 23;7(357):ra121. doi: 10.1126/scisignal.aaa1877.

33.

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ.

PLoS One. 2014 Jul 1;9(7):e101286. doi: 10.1371/journal.pone.0101286. eCollection 2014.

34.

Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions.

Kwong LN, Chin L.

Cancer Res. 2014 Mar 15;74(6):1814-21. doi: 10.1158/0008-5472.CAN-13-1446. Epub 2014 Jan 22.

35.

A systems biology approach to personalizing therapeutic combinations.

Kwong LN, Heffernan TP, Chin L.

Cancer Discov. 2013 Dec;3(12):1339-44. doi: 10.1158/2159-8290.CD-13-0394.

36.

Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma.

Kwong LN, Davies MA.

Clin Cancer Res. 2013 Oct 1;19(19):5310-9. doi: 10.1158/1078-0432.CCR-13-0142. Review.

37.

Targeted therapy for melanoma: rational combinatorial approaches.

Kwong LN, Davies MA.

Oncogene. 2014 Jan 2;33(1):1-9. doi: 10.1038/onc.2013.34. Epub 2013 Feb 18. Review.

PMID:
23416974
38.

Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.

Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L.

Nat Med. 2012 Oct;18(10):1503-10. doi: 10.1038/nm.2941. Epub 2012 Sep 16. Erratum in: Nat Med. 2012 Dec;18(12):1857.

39.

Cerebral white matter lesions in patients with Crohn's disease.

Chen M, Lee G, Kwong LN, Lamont S, Chaves C.

J Neuroimaging. 2012 Jan;22(1):38-41. doi: 10.1111/j.1552-6569.2010.00538.x. Epub 2010 Nov 17.

PMID:
21091817
40.

Non-germline genetically engineered mouse models for translational cancer research.

Heyer J, Kwong LN, Lowe SW, Chin L.

Nat Rev Cancer. 2010 Jul;10(7):470-80. doi: 10.1038/nrc2877. Review.

41.

Integrative genome comparison of primary and metastatic melanomas.

Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, Brennan C, Chin L.

PLoS One. 2010 May 24;5(5):e10770. doi: 10.1371/journal.pone.0010770.

42.

The brothers RAF.

Kwong LN, Chin L.

Cell. 2010 Jan 22;140(2):180-2. doi: 10.1016/j.cell.2010.01.013.

43.

APC and its modifiers in colon cancer.

Kwong LN, Dove WF.

Adv Exp Med Biol. 2009;656:85-106. Review.

44.

The metastasis problem gets stickier.

Kwong LN, Chin L.

Cancer Cell. 2009 Jan 6;15(1):1-2. doi: 10.1016/j.ccr.2008.12.007.

45.

Atm is a negative regulator of intestinal neoplasia.

Kwong LN, Weiss KR, Haigis KM, Dove WF.

Oncogene. 2008 Feb 7;27(7):1013-8. Epub 2007 Aug 13.

46.

Identification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18.

Kwong LN, Shedlovsky A, Biehl BS, Clipson L, Pasch CA, Dove WF.

Genetics. 2007 Jun;176(2):1237-44. Epub 2007 Apr 15.

47.

A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer.

Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, Haag JD, Chen KS, Waller JL, Gould MN, Dove WF.

Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4036-41. Epub 2007 Feb 27.

Supplemental Content

Loading ...
Support Center